Based on our findings, the combinatorial treatment strategy could be applied to increase the sensitivity to immune checkpoint inhibitors in immunogenic melanomas that already harbor abundant infiltrating CD8+ T cells, especially for those that might be adaptively resistant to anti-PD-1 immunotherapy. This evidence concerns the gene CD8A and melanoma.